Samer Al Hadidi/LinkedIn
Mar 31, 2025, 12:10
Samer Al Hadidi: Daratumumab for high-risk smoldering multiple myeloma – Are we there yet?
Samer Al Hadidi, Associate Professor at UAMS – University of Arkansas for Medical Sciences, posted on X:
“Check our recent editorial discussing AQUILA study.
Daratumumab for high-risk smoldering multiple myeloma – are we there yet?”
Authors: Bhavesh Mohan Lal, Samer Al Hadidi
Read more posts featuring Myeloma at OncoDaily.com.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53
Apr 1, 2025, 11:51
Apr 1, 2025, 11:42